FL-XLEAR
2.12.2020 10:34:38 CET | Business Wire | Press release
New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains...” The Virucidal studies were independently funded.
“The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said Dr. Gustavo Ferrer, who is leading the research team.
State of scientific research:
Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19. Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19). https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2768627 .
Xlear’s components are antiviral—they block viral adhesion in the nose . See, for example, https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full.pdf . This Univ. of Tennessee study on SARS-CoV-2 concluded: “antiviral nasal sprays...contribute reduce...viral load...slowing down disease progression...and transmission...”
Peer-reviewed case studies indicate Xlear helps in treating COVID-19: First-look trial at Larkin Community Hospital (Miami), determined: “symptomatic, COVID-19 patients, treated with [Xlear], as an adjunct to...[standard care],” showed “rapid clinical improvement and shorten[ed] time” to negative COVID-19 PCR tests. https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extract-nasal-spray-solution-in-covid-19-case-series .
Xlear has been used for over 20 years by millions of people worldwide without a single significant adverse incident report.
“Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2). This combination of antiviral and virucidal capabilities is an important one-two punch in fighting the virus,” said Nathan Jones, CEO of Xlear. “With the pandemic raging worldwide, we must use every tool we can to fight it. Failing that needlessly risks millions of lives. Weighing our 20-year safety record, against the risks of this deadly virus, it’s clear Xlear needs to be in widespread use,” Jones concluded.
Full study: https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
More information on Xlear: https://xlear.com/
About Dr. Gustavo Ferrer
Dr. Ferrer, MD FCCP, is an Associate Professor of Medicine and Founder of the Cleveland Clinic Florida Interstitial Lung Disease Clinic and the Aventura Hospital Pulmonary and Critical Care fellowship. He currently serves as President of Intensive Care Experts/Aventura Pulmonary Institute and previously served as United Nations University Director of Respiratory Research, Venezuela.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005291/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vultr and SUSE Launch Validated Full-Stack NVIDIA Enterprise AI Platform to Accelerate Production Deployments8.7.2026 10:00:00 CEST | Press release
SUSE AI Factory with NVIDIA on Vultr Infrastructure delivers integrated enterprise AI software, GPU acceleration, and global cloud infrastructure to move organizations from AI experimentation to secure production Vultr, the world's largest privately-held cloud infrastructure company, today announced the launch of SUSE AI Factory with NVIDIA on Vultr infrastructure, developed in partnership with SUSE. Announced alongside SUSE at the RAISE Summit in Paris, this validated, full-stack enterprise AI platform combines enterprise-grade AI software, advanced GPU acceleration, and global AI infrastructure into a single, production-ready solution. As organizations look to move AI workloads from experimentation into production, this joint solution eliminates the complexity of building AI stacks from scratch, allowing enterprises to deploy secure, scalable AI applications with ease. The solution combines software and infrastructure capabilities to help organizations securely and reliably advance a
NetApp Named Presenting Partner of 2026 NFL Madrid Game8.7.2026 10:00:00 CEST | Press release
League’s Official Intelligent Data Infrastructure Partner Extends Its Presence Across the NFL’s International Games The NFL today announced that the league’s Global Partner, NetApp (NASDAQ: NTAP), the Intelligent Data Infrastructure company, will return as Presenting Partner of the 2026 NFL Madrid Game, featuring the Atlanta Falcons taking on the Cincinnati Bengals at the Bernabéu Stadium — home to Real Madrid C.F. — on Sunday, Nov. 8. The multi-year announcement builds on NetApp’s role as the league’s Official Intelligent Data Infrastructure Partner and Presenting Partner of the inaugural NFL Madrid Game in 2025 and continues the company’s support of the league’s international games. “We are delighted to welcome NetApp back as Presenting Partner of the NFL Madrid Game,” said Rafa De Los Santos, country manager of NFL Spain. “Last year’s game at the Bernabéu was a landmark moment for the NFL in Spain, and with the Falcons and Bengals bringing two of the most exciting teams in football
MSIG Europe Selects Clearwater Analytics to Modernize Investment Operations8.7.2026 10:00:00 CEST | Press release
Selection extends MS&AD Group’s global relationship with Clearwater, bringing a unified platform for investment data, accounting, regulatory reporting, and analytics to MSIG Europe Clearwater Analytics today announced that MSIG Europe, a wholly owned subsidiary of MS&AD Insurance Group, has selected the Clearwater platform to modernize its operating model, unify data across the investment lifecycle, and meet the demands of the European regulatory environment, including Belgian GAAP, IFRS and Solvency II. European insurers are navigating the convergence of tightening regulatory demands, growing allocations to private markets, and the operational limits of fragmented legacy systems. The firms moving fastest are consolidating onto platforms that deliver daily accuracy, compliance automation, and integrated analytics at scale. MSIG is a wholly-owned subsidiary of Mitsui Sumitomo Insurance and a member of the MS&AD Insurance Group, one of Asia’s leading non-life insurance brands with a pres
Samsung Begins Mass Production of PM1763 SSD Optimized for Next-Generation AI Infrastructure8.7.2026 09:30:00 CEST | Press release
PCIe 6.0-based enterprise SSD delivers outstanding performance and enhanced power efficiency for AI and HPC servers9th-generation V-NAND, 4nm controller and liquid-cooling optimization support demanding AI workloads Samsung Electronics Co., Ltd., a global leader in advanced memory technology, today announced mass production of PM1763, the company’s PCIe® 6.0-based enterprise solid state drive (SSD) optimized for next-generation AI and HPC server environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708516273/en/ Samsung Begins Mass Production of PM1763 SSD Optimized for Next-Generation AI Infrastructure As the volume of data required for AI training and inference continues to grow rapidly, enterprise SSDs (eSSDs) capable of delivering data quickly and reliably are becoming increasingly essential to AI infrastructure. Featuring high-speed data transfer and an optimized controller architecture, PM1763 is expected to
FPT Releases Global Study on Scaling Enterprise AI, Highlighting the Shift from Pilots to Platform-Driven Transformation8.7.2026 09:08:00 CEST | Press release
As artificial intelligence moves from experimentation into the core of enterprise operations, a new reality is emerging: scaling AI is no longer a technology challenge, but a transformation imperative. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708088519/en/ FPT Corporation today announced the release of a global thought leadership study, titled “From Pilots to Reusable Platforms: A Blueprint for Scaling Enterprise AI.” Published on 08 July 2026, this is a commissioned study conducted by Forrester Consulting on behalf of FPT, examining how enterprises across regions and industries are advancing their AI journeys - and why many remain unable to translate early momentum into consistent, enterprise-wide impact. The executive study is based on a global survey of 397 business and technology decision-makers globally, supported by in-depth interviews with senior executives across North America, Europe, Asia Pacific and Japan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom